Given that current drugs, such as tofacitinib and peficitinib, target the JAK3 signaling pathway, our findings support the potential role of JAK3-targeted therapy to improve treatment options for PTLD (37–39). Here, JAK3 is linked to post-transplant lymphoproliferative disease.